Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in USD (TTM)5.90m
- Net income in USD-87.96m
- Incorporated2004
- Employees73.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | 0.00 | -203.85m | 661.87m | 150.00 | -- | 4.95 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 668.93m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.77m | -171.22m | 674.71m | 483.00 | -- | 1.70 | -- | 24.29 | -1.34 | -1.34 | 0.2185 | 3.08 | 0.042 | -- | 26.88 | 57,500.75 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 168.77m | -213.47m | 679.85m | 709.00 | -- | 2.81 | -- | 4.03 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 682.32m | 266.00 | -- | -- | -- | 6.17 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| ProKidney Corp | 0.00 | -38.68m | 692.32m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Mesoblast Ltd (ADR) | 5.90m | -87.96m | 710.42m | 73.00 | -- | 1.47 | -- | 120.37 | -0.8761 | -0.8761 | 0.0598 | 4.21 | 0.0088 | -- | 3.21 | 80,849.31 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 722.02m | 267.00 | 104.61 | -- | 78.30 | 1.80 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Savara Inc | 0.00 | -75.29m | 730.83m | 37.00 | -- | 6.03 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Annexon Inc | 0.00 | -115.16m | 732.18m | 71.00 | -- | 2.03 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 733.58m | 80.00 | -- | 3.23 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 752.69m | 107.00 | -- | 2.39 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Replimune Group Inc | 0.00 | -220.01m | 757.00m | 331.00 | -- | 1.77 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 762.25m | 58.00 | -- | 2.26 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Dianthus Therapeutics Inc | 4.12m | -56.68m | 763.21m | 53.00 | -- | 2.13 | -- | 185.34 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Data as of Sep 19 2024. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
0.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Group One Trading LPas of 30 Jun 2024 | 227.77k | 0.20% |
| Summit X LLCas of 30 Jun 2024 | 147.69k | 0.13% |
| Penbrook Management LLCas of 30 Jun 2024 | 124.93k | 0.11% |
| Prosperity Wealth Management, Inc.as of 30 Jun 2024 | 90.17k | 0.08% |
| Marshall Wace LLPas of 30 Jun 2024 | 82.58k | 0.07% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 78.08k | 0.07% |
| Citadel Securities LLCas of 30 Jun 2024 | 77.29k | 0.07% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 72.69k | 0.06% |
| Aperio Group LLCas of 30 Jun 2024 | 70.23k | 0.06% |
| Chase Investment Counsel Corp.as of 30 Jun 2024 | 59.60k | 0.05% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
